moxifloxacin has been researched along with sulbactam in 12 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (sulbactam) | Trials (sulbactam) | Recent Studies (post-2010) (sulbactam) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 1,844 | 297 | 488 |
| Protein | Taxonomy | moxifloxacin (IC50) | sulbactam (IC50) |
|---|---|---|---|
| Beta-lactamase | Escherichia coli | 6.2 | |
| Beta-lactamase | Shouchella clausii | 0.075 | |
| Beta-lactamase | Pseudomonas aeruginosa | 0.37 | |
| Beta-lactamase | Pseudomonas aeruginosa | 3 | |
| Beta-lactamase | Aeromonas allosaccharophila | 4 | |
| Beta-lactamase | Staphylococcus aureus | 6.5 | |
| Beta-lactamase | Enterobacter cloacae | 1.4 | |
| Beta-lactamase TEM | Escherichia coli | 4.3 | |
| Beta-lactamase | Acinetobacter pittii | 1.12 | |
| Beta-lactamase | Acinetobacter pittii | 7.758 | |
| Beta-lactamase | Pseudomonas aeruginosa | 3 | |
| Beta-lactamase | Escherichia coli | 2.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Calvo, A; García, R; Gómez-Lus, ML; Leturia, A; Sevillano, D; Valero, E | 1 |
| Al-Nawas, B; Callaway, A; Geibel, MA; Karbach, J; Wagner, W; Willershausen, B | 1 |
| Allewelt, M; Lode, H; Lorenz, J; Ott, SR; Reimnitz, P | 1 |
| Huber, W; Kamereck, K; Prinz, C; Schmid, RM; Voland, P; Weber, A; Weidenbach, H; Winkle, P | 1 |
| Al-Nawas, B; d'Hoedt, B; Karbach, J; Mouratidou, A | 1 |
| Chen, CW; Ma, CJ; Ming, CC; Shan, YS; Wang, JY; Yeh, YS | 1 |
| Akgul, O; Jean-Pierre, H; Justesen, US; Kulekci, G; Morris, T; Nagy, E; Soyletir, G; Ulger Toprak, N; Urban, E; Veloo, ACM; Wybo, I | 1 |
| Heidary, G; Somsen, D | 1 |
| Ikebuchi, K; Imai, K; Kawamura, T; Kodana, M; Maeda, T; Maesaki, S; Mitsutake, K; Murakami, T; Ogane, K; Onodera, A; Sakai, J; Takeuchi, S; Tarumoto, N | 1 |
2 trial(s) available for moxifloxacin and sulbactam
| Article | Year |
|---|---|
Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess.
Topics: Adult; Ampicillin; Anti-Bacterial Agents; Aza Compounds; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Gram-Negative Facultatively Anaerobic Rods; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Lung Abscess; Male; Moxifloxacin; Pneumonia, Aspiration; Quinolines; Radiography; Sulbactam | 2008 |
Prospective, randomized, study of ampicillin-sulbactam versus moxifloxacin monotherapy for the treatment of community-acquired complicated intra-abdominal infections.
Topics: Adult; Aged; Aged, 80 and over; Ampicillin; Analysis of Variance; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Intraabdominal Infections; Logistic Models; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Risk Factors; Sulbactam; Taiwan; Treatment Outcome; Young Adult | 2013 |
10 other study(ies) available for moxifloxacin and sulbactam
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
Topics: Acinetobacter; Acinetobacter Infections; Ampicillin; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Opportunistic Infections; Quinolines; Sulbactam; Thienamycins | 2001 |
Antibiotic resistance testing of the total implant-associated micro-flora and its pure isolates.
Topics: Ampicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria, Anaerobic; Dental Implants; Dental Plaque; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Cocci; Gram-Positive Rods; Humans; In Vitro Techniques; Male; Microbial Sensitivity Tests; Moxifloxacin; Penicillin G; Quinolines; Sulbactam | 2007 |
In vitro activity of moxifloxacin and piperacillin/sulbactam against pathogens of acute cholangitis.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bile; Cholangitis; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enterococcus; Escherichia coli; Female; Fluoroquinolones; Humans; Klebsiella; Male; Middle Aged; Moxifloxacin; Piperacillin; Prospective Studies; Quinolines; Sulbactam | 2008 |
Antibiotic susceptibility of cocultures in polymicrobial infections such as peri-implantitis or periodontitis: an in vitro model.
Topics: Acetamides; Actinobacillus Infections; Aggregatibacter actinomycetemcomitans; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Capnocytophaga; Coculture Techniques; Coinfection; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Linezolid; Metronidazole; Microbial Interactions; Minocycline; Moxifloxacin; Oxazolidinones; Penicillin G; Peptostreptococcus; Peri-Implantitis; Periodontitis; Quinolines; Sulbactam | 2011 |
A multicenter survey of antimicrobial susceptibility of Prevotella species as determined by Etest methodology.
Topics: Ampicillin; Anti-Bacterial Agents; Bacteroidaceae Infections; Clindamycin; Disk Diffusion Antimicrobial Tests; Fluoroquinolones; Humans; Kuwait; Meropenem; Metronidazole; Moxifloxacin; Prevotella; Sulbactam; Thienamycins; Turkey | 2018 |
Rapid onset of orbital cellulitis after uncomplicated strabismus surgery.
Topics: Administration, Ophthalmic; Ampicillin; Anti-Bacterial Agents; Child; Drug Therapy, Combination; Esotropia; Eye Infections, Bacterial; Humans; Male; Moxifloxacin; Oculomotor Muscles; Ophthalmic Solutions; Orbital Cellulitis; Postoperative Complications; Streptococcal Infections; Streptococcus pyogenes; Sulbactam; Tomography, X-Ray Computed; Vancomycin | 2019 |
Antimicrobial susceptibility and prevalence of resistance genes in Bacteroides fragilis isolated from blood culture bottles in two tertiary care hospitals in Japan.
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Proteins; Bacteroides fragilis; Bacteroides Infections; beta-Lactamases; Blood Culture; DNA Transposable Elements; Doripenem; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Humans; Imipenem; Japan; Meropenem; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Piperacillin, Tazobactam Drug Combination; Prevalence; Sulbactam; Tertiary Care Centers | 2020 |